Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
ab
Description:
The term “ab” is ambiguous here, referring variously to a German prefix and possibly an abbreviation in biomedical contexts.
OpenAlex ID:
keywords/ab
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
2015
·
James Larkin
, Vanna Chiarion-Sileni
, et al.
·
New England Journal of Medicine
·
8,802
PDF
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
2016
·
Eric L. Simpson
, Thomas Bieber
, et al.
·
New England Journal of Medicine
·
2,286
PDF
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
2007
·
Ian Smith
, Marion Procter
, et al.
·
The Lancet
·
1,660
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
2019
·
Caroline Robert
, Antoni Ribas
, et al.
·
The Lancet Oncology
·
1,282
PDF
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
2020
·
Philippe Gevaert
, Theodore A. Omachi
, et al.
·
Journal of Allergy and Clinical Immunology
·
821
PDF
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
2012
·
M. Reck
, I. Bondarenko
, et al.
·
Annals of Oncology
·
642
PDF
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
2019
·
Sherene Loi
, Anita Giobbie-Hurder
, et al.
·
The Lancet Oncology
·
514
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial
2021
·
Hope S. Rugo
, Seock-Ah Im
, et al.
·
JAMA Oncology
·
389
PDF
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
2018
·
N. Boku
, M.-H. Ryu
, et al.
·
Annals of Oncology
·
340
Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
2008
·
Holger Thiele
, Kathrin Schindler
, et al.
·
Circulation
·
320
PDF
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
2020
·
Noa Biran
, Andrew Ip
, et al.
·
The Lancet Rheumatology
·
292
PDF
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
2023
·
David A. Sallman
, Monzr M. Al Malki
, et al.
·
Journal of Clinical Oncology
·
215
PDF
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
2023
·
Masatoshi Kudo
, Tomoko Aoki
, et al.
·
Liver Cancer
·
181
PDF
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
2015
·
Leticia De Mattos-Arruda
, Giulia Bottai
, et al.
·
Oncotarget
·
164
PDF
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study
2013
·
Paul Sabbatini
, Philipp Harter
, et al.
·
Journal of Clinical Oncology
·
153
PDF
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
2008
·
Stefano Cascinu
, Rossana Berardi
, et al.
·
The Lancet Oncology
·
145
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor
2007
·
Philipp Steiner
, Christopher Joynes
, et al.
·
Clinical Cancer Research
·
127
PDF
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023
·
Laurent Peyrin-Biroulet
, Jessica R. Allegretti
, et al.
·
Gastroenterology
·
119
PDF
Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial
2020
·
Thorsten M. Leucker
, Michael J. Blaha
, et al.
·
Circulation
·
111
PDF
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
2022
·
Masatoshi Kudo
, Richard S. Finn
, et al.
·
Liver Cancer
·
95
PDF
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
2022
·
Xiangrui Meng
, Tao Wu
, et al.
·
The Lancet. Gastroenterology & hepatology
·
94
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
2024
·
Tycel Jovelle Phillips
, Carmelo Carlo-Stella
, et al.
·
Journal of Clinical Oncology
·
93
Five-year outcomes with alemtuzumab induction after lung transplantation
2011
·
Susan Shyu
, Mary Amanda Dew
, et al.
·
The Journal of Heart and Lung Transplantation
·
91
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
2023
·
Neal E Ready
, Clarisse Audigier-Valette
, et al.
·
Journal for ImmunoTherapy of Cancer
·
88
PDF
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
2021
·
Jarushka Naidoo
, Karisa C Schreck
, et al.
·
Journal for ImmunoTherapy of Cancer
·
74
PDF
Show more works
View as search
Works count:
347
Citation count:
20,780
Year
Topic
Type